ZURA Zura Bio Limited
Financings ·
Zura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment.
Shareholders will surrender 3.5 million and 3.0 million Class A ordinary shares for no consideration and receive pre-funded warrants with a $0.001 exercise price.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $42.1 million | $24.4 million |
| Net income (loss) | -$68.7 million | -$52.4 million |
| Cash from operations | -$64.8 million | -$28.1 million |
| Cash and equivalents | $109.4 million | $176.5 million |
Zura Bio Limited trades under the ticker ZURA on NASDAQ.
Zura Bio Limited is listed on NASDAQ. Our directory also records these other listings: LS:A3D7LY; LSX:A3D7LY.
The SEC Central Index Key (CIK) for Zura Bio Limited is 1855644. Its filings are on SEC EDGAR.
95,829,137 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Zura Bio Limited under United States.
Our directory classifies Zura Bio Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Zura Bio Limited is KYG9TY5A1016.
aibio.space lists Zura Bio Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Zura Bio Limited reported a net loss of $68.7 million for the fiscal year ended Dec 31, 2025, and used $64.8 million of cash in operations, per its annual report to the SEC.
$42.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$187.7 million in cash at Sep 30, 2026, per its 10-Q.
Our latest story on Zura Bio, dated Jan 2, 2026: "Zura Bio to issue 8,657,402 shares and pay $7,325,000 to Athanor Capital, ends Stone Peach deals". Zura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment. Source.
Our latest financing story, dated Jan 2, 2026: "Zura Bio to issue 8,657,402 shares and pay $7,325,000 to Athanor Capital, ends Stone Peach deals". Zura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment. Source.
We do not publish live share prices. In its annual report, Zura Bio Limited put the market value of shares held by non-affiliates (public float) at $59.0 million as of Jun 30, 2025.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio